Quantum Surgical begins the industrial phase of its medical robot

Five years after its creation (2017) in Montpellier, the company Quantum Surgical, specialized in surgical robotics, inaugurated, on October 3, its new head office in the Millénaire district.

The company designs medical robots for the minimally invasive treatment of cancer, for percutaneous interventional procedures. She thus designed the Epione robot, a curative and early interventional assistance in oncology, for cancers of the abdomen (liver and kidney). The tool, less invasive than surgery, makes it possible to plan, target, deliver and confirm the removal of tumours: the surgeon programs the trajectory on his screen via the software, the robot positions itself according to this trajectory and the surgeon can thus proceed with great precision to the ablation of the cancerous tumour.

It’s a real change of scale for Quantum Surgical, underlines Bertin Nahum, president and founder of the company, well known in the sector for having already created MedTech in Montpellier, bought in 2016 by the American Zimmer Biomet. In five years, we have grown from four partners to around a hundred employees today. Our campus is now fully adapted to our industrial growth and the pace of development of our activities. In these two 2,400 m2 buildings, 700 m2 will be dedicated to the production of robots and 1,000 m2 to R&D. »

“Hospital establishments that are benchmarks”

Thanks to scientific partnerships, in particular with the University Hospital of Montpellier and the Gustave Roussy Institute in Villejuif, 80 patients with abdominal cancer – particularly of the liver – have to date been able to benefit from care using Epione.

Off-label, the robot can also be used for other cancers, such as lung, if the surgeon deems it relevant », specifies Professor Thierry De Baere, head of the therapeutic imaging department at the Gustave Roussy hospital.

Between June 2018 and October 2021, Quantum Surgical had raised 50 million euros from the Ally Bridge Group fund (based in Hong Kong and New York), specializing in the medical and life sciences sector, from the European Bank of investment, Bpifrance and of the Caisse d’Epargne Languedoc-Roussillon.

The medtech is continuing its deployment in France, but also in Europe and the United States where it has obtained the required approvals, and in China (where approvals are in progress) via a joint venture. A sales team is already established in the United States.

But we proceed with caution, so as to be able to meet demand, but also to be able to support the adoption of the robot and build its reputation, indicates Fernand Badano, associate of Bertin Nahum with Sophie Roca and Lucien Blondel. There is still market education to be done… This is why we want to give priority to equipping hospitals that are benchmarks in oncology. »

100 units installed by 2025

The production of robots will now ramp up, the objective being to reach 100 units installed by 2025. The number of employees should also grow, up to 300 worldwide by 2025, with a forecast turnover of 30 million euros that year, with the leaders of Quantum Surgical announcing strong deployment between 2026 and 2030.

Another milestone for Quantum Surgical: “ extend the indications of Epione technology, in particular to support the development of decision support functionalities based on artificial intelligence algorithms “.

To support the market launch of the Epione robot (the price of which is around one million euros) and to continue R&D efforts, the company is planning a new fundraising of 100 to 150 million euros in 2023, presumably from foreign funds and probably from American funds.